Better Times Ahead For Vanda Pharmaceuticals Inc (NASDAQ: VNDA)?

Vanda Pharmaceuticals Inc (VNDA) concluded trading on Wednesday at a closing price of $5.05, with 50.6 million shares of worth about $255.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 21.10% during that period and on April 3, 2024 the price saw a gain of about 29.16%. Currently the company’s common shares owned by public are about 57.53M shares, out of which, 54.51M shares are available for trading.

Stock saw a price change of 30.83% in past 5 days and over the past one month there was a price change of 18.27%. Year-to-date (YTD), VNDA shares are showing a performance of 19.67% which decreased to -25.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.30 but also hit the highest price of $7.00 during that period. The average intraday trading volume for Vanda Pharmaceuticals Inc shares is 985.15K. The stock is currently trading 29.58% above its 20-day simple moving average (SMA20), while that difference is up 26.27% for SMA50 and it goes to 8.90% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) currently have 57.53M outstanding shares and institutions hold larger chunk of about 89.15% of that.

The stock has a current market capitalization of $290.58M and its 3Y-monthly beta is at 0.78. PE ratio of stock for trailing 12 months is 115.56, while it has posted earnings per share of $0.04 in the same period. Its PEG reads 3.20 and has Quick Ratio of 4.92 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VNDA, volatility over the week remained 10.87% while standing at 5.40% over the month.

Analysts are in expectations that Vanda Pharmaceuticals Inc (VNDA) stock would likely to be making an EPS of $0.05 in the current quarter, while forecast for next quarter EPS is $0.02 and it is -$0.48 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.05 which is $0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -75.00% while it is estimated to decrease by -4900.00% in next year. EPS is likely to grow at an annualized rate of 36.10% for next 5-years, compared to annual growth of -37.98% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on February 25, 2022 offering a Hold rating for the stock and assigned a target price range of between $24 and $12 to it. Coverage by BofA Securities stated Vanda Pharmaceuticals Inc (VNDA) stock as a Buy in their note to investors on May 12, 2021, suggesting a price target of $22 for the stock. On January 14, 2021, Citigroup Downgrade their recommendations, while on October 29, 2020, Citigroup Upgrade their ratings for the stock with a price target of $14. Stock get a Neutral rating from Citigroup on June 09, 2020.

Most Popular

Related Posts